SRx Health Solutions Announces Receipt of Late Filing Notification Letter from NYSE American
SRx Health Solutions (NYSE American: SRXH) has received a notice of non-compliance from NYSE American due to failing to file its Q2 2025 10-Q report by the August 19, 2025 deadline. The company has been granted an initial six-month cure period to file the delinquent report, with the possibility of an additional six-month extension at the Exchange's discretion.
While this notification does not immediately impact SRXH's stock listing or trading status, the company must address this filing delinquency to maintain its listing. Management states they are working with auditors to complete the filing and expects to submit the report before the cure period deadline.
SRx Health Solutions (NYSE American: SRXH) ha ricevuto una comunicazione di non conformità da NYSE American per il mancato deposito del modulo 10-Q relativo al secondo trimestre 2025 entro la scadenza del 19 agosto 2025. Alla società è stato concesso un periodo iniziale di sei mesi per regolarizzare la posizione, con la possibilità che la Borsa conceda un'ulteriore proroga di altri sei mesi a sua discrezione.
La notifica non determina al momento la sospensione della quotazione o delle negoziazioni, tuttavia SRXH deve sanare il ritardo nelle comunicazioni per mantenere la quotazione. La direzione afferma di essere al lavoro con i revisori per completare il deposito e prevede di presentare il rapporto entro il termine del periodo di cure.
SRx Health Solutions (NYSE American: SRXH) ha recibido un aviso de incumplimiento por parte de NYSE American por no presentar su informe 10-Q del segundo trimestre de 2025 antes del 19 de agosto de 2025. A la compañía se le ha otorgado un periodo inicial de corrección de seis meses, con la posibilidad de una prórroga adicional de seis meses a discreción de la Bolsa.
Esta notificación no afecta de inmediato la cotización ni el comercio de las acciones de SRXH, pero la empresa debe subsanar el retraso en la presentación para conservar su listado. La dirección indica que está trabajando con los auditores para finalizar el informe y espera presentarlo antes de que venza el periodo de corrección.
SRx Health Solutions (NYSE American: SRXH)는 2025회계연도 2분기 10-Q 보고서를 2025년 8월 19일 마감일까지 제출하지 않아 NYSE American으로부터 비준수 통보를 받았습니다. 회사에는 체불 보고서를 제출할 수 있도록 초기 6개월의 시정 기간이 부여되었으며, 거래소 재량에 따라 추가로 6개월 연장될 수 있습니다.
해당 통보가 즉시 SRXH의 상장이나 거래 상태에 영향을 주지는 않지만, 상장을 유지하려면 제출 지연을 해소해야 합니다. 경영진은 감사인과 협력해 보고서 작성 작업을 진행 중이며 시정 기간 내에 제출할 계획이라고 밝혔습니다.
SRx Health Solutions (NYSE American: SRXH) a reçu un avis de non-conformité de la part de NYSE American pour ne pas avoir déposé son rapport 10-Q du deuxième trimestre 2025 avant la date limite du 19 août 2025. La société bénéficie d'une période initiale de correction de six mois pour déposer le document manquant, avec la possibilité d'une extension supplémentaire de six mois à la discrétion de la Bourse.
Cette notification n'affecte pas immédiatement la cotation ou le trafic des actions SRXH, mais la société doit régulariser ce retard de dépôt pour conserver sa cotation. La direction indique qu'elle travaille avec les auditeurs pour finaliser le rapport et prévoit de le soumettre avant la fin de la période de correction.
SRx Health Solutions (NYSE American: SRXH) hat von der NYSE American eine Mitteilung über Nicht‑Einhaltung erhalten, weil der 10-Q-Bericht für das zweite Quartal 2025 nicht bis zum 19. August 2025 eingereicht wurde. Dem Unternehmen wurde eine anfängliche sechsmonatige Nachfrist zur Einreichung des ausstehenden Berichts gewährt, mit der Möglichkeit einer weiteren sechsmonatigen Verlängerung nach Ermessen der Börse.
Diese Mitteilung hat derzeit keine unmittelbaren Auswirkungen auf die Notierung oder den Handel der SRXH-Aktie, jedoch muss das Unternehmen die Fristversäumnis beheben, um die Notierung zu erhalten. Das Management erklärt, man arbeite mit den Abschlussprüfern zusammen, um die Einreichung abzuschließen, und rechnet damit, den Bericht vor Ablauf der Nachfrist einzureichen.
- Company maintains its NYSE American listing status despite the delay
- Additional six-month cure period may be granted if needed
- Failure to timely file Q2 2025 10-Q report
- Risk of potential delisting if compliance is not achieved within cure period
- Possible indication of internal control or accounting issues
Insights
SRx Health Solutions faces NYSE compliance issues due to late quarterly filing, with potential listing implications if not resolved within cure period.
SRx Health Solutions has failed to file its Q2 2025 quarterly report (10-Q) by the August 19 deadline, triggering a non-compliance notice from NYSE American. This places the company in violation of Section 1007 of the NYSE American Company Guide, which governs timely filing requirements for listed securities.
The company now enters an initial six-month cure period during which NYSE will monitor their progress toward filing the delinquent report. If SRx fails to resolve the issue within this timeframe, the exchange may grant an additional six-month period at its discretion, depending on the company's circumstances.
While the notice doesn't immediately affect the stock's listing or trading status, continued non-compliance could eventually lead to delisting proceedings. The company has stated it's working with auditors to complete the filing and expects to submit the report before the cure period deadline.
Late filings of this nature often raise questions about potential underlying issues, which could range from accounting complexities to more serious concerns about financial reporting controls. However, SRx has expressed confidence in its ability to regain compliance with all NYSE listing standards, suggesting the delay may be administrative rather than indicative of material financial problems.
TAMPA, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that on August 20, 2025, it received an official notice from NYSE Regulation indicating that the Company is not in compliance with the continued listing standards of NYSE American LLC (the “Exchange”) as set forth in Section 1007 of the NYSE American Company Guide. The notice was issued because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Delinquent Report”) with the Securities and Exchange Commission (the “SEC”) by the required due date of August 19, 2025.
During the six-month period from the date of the Filing Delinquency (the "Initial Cure Period"), the Exchange will monitor the Issuer and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Issuer, until the Filing Delinquency is cured. If the Issuer fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in the Exchange's sole discretion, allow the Issuer's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Issuer's specific circumstances.
The Company is working diligently with its auditors and advisors to complete the Delinquent Report as soon as practicable. The Company is currently anticipating filing the Delinquent Report on or before the cure period deadline.
This notice does not immediately affect the listing or trading of the Company’s common stock on the Exchange. The Company intends to regain compliance with the Exchange’s listing standards. While there can be no assurance that it will regain compliance with all applicable Exchange listing standards, the Company is confident it will comply with all listing standards.
About SRx Health Solutions, Inc.
SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians. For more information on SRx Health Solutions Inc., please visit www.srxhealth.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com
FAQ
Why did SRx Health Solutions (SRXH) receive a notice from NYSE American?
Will SRXH be delisted from NYSE American due to the late filing notice?
When does SRXH expect to file its delayed Q2 2025 10-Q report?
What are the consequences of the NYSE American notification for SRXH?
How long does SRXH have to resolve the filing delinquency?
